Suzuken Co Ltd (Suzuken) is primarily engaged in pharmaceutical distribution, healthcare product development, community healthcare and nursing care support, and healthcare-related services. The company provides a stable supply of pharmaceuticals, optimizes distribution inventory, and contributes to the reduction of social costs through its pharmaceutical distribution business.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Suzuken is focusing its R&D initiatives on the development of new pharmaceuticals, particularly in the areas of diabetes, and kidney and dialysis-related areas. These areas are identified as having substantial unmet medical needs and strong potential as new growth markets. The R&D initiatives are guided by policies such as promoting development themes, acquiring late-stage clinical development products through in-licensing, converting research themes into development themes early, and enhancing the drug discovery pipeline through external collaboration. Its major projects include the development of SK-5307 (Paltusotine) for acromegaly and neuroendocrine tumors, SK-2407 (ATN1-ASO) for dentatorubral-pallidoluysian atrophy, and the promotion of OSDrC (dry-coated tableting technology) business. In FY2025, the company incurred research and development expenses of JPY3,279 million.